154235-83-3 | Piperidin-1-yl(quinoxalin-6-yl)methanone

453-71-4    154235-83-3 

[1]Hu,Bin;Toda,Kosuke;Wang,Xiaoyu;Antczak,MonikaI.;Smith,Julianne;Geboers,Sophie;Nishikawa,Gen;Li,Hongyun;Dawson,Dawn;Fink,Stephen;Desai,AmarB.;Williams,NoelleS.;Markowitz,SanfordD.;Ready,JosephM.[JournalofMedicinalChemistry,2022,vol.65,#22,p.15327-15343]

CASUnavailable 

  154235-83-3 

[1]Hu,Bin;Toda,Kosuke;Wang,Xiaoyu;Antczak,MonikaI.;Smith,Julianne;Geboers,Sophie;Nishikawa,Gen;Li,Hongyun;Dawson,Dawn;Fink,Stephen;Desai,AmarB.;Williams,NoelleS.;Markowitz,SanfordD.;Ready,JosephM.[JournalofMedicinalChemistry,2022,vol.65,#22,p.15327-15343]

1096823-37-8    154235-83-3 

[1]Hu,Bin;Toda,Kosuke;Wang,Xiaoyu;Antczak,MonikaI.;Smith,Julianne;Geboers,Sophie;Nishikawa,Gen;Li,Hongyun;Dawson,Dawn;Fink,Stephen;Desai,AmarB.;Williams,NoelleS.;Markowitz,SanfordD.;Ready,JosephM.[JournalofMedicinalChemistry,2022,vol.65,#22,p.15327-15343]

2241677-03-0    154235-83-3 

[1]Hu,Bin;Toda,Kosuke;Wang,Xiaoyu;Antczak,MonikaI.;Smith,Julianne;Geboers,Sophie;Nishikawa,Gen;Li,Hongyun;Dawson,Dawn;Fink,Stephen;Desai,AmarB.;Williams,NoelleS.;Markowitz,SanfordD.;Ready,JosephM.[JournalofMedicinalChemistry,2022,vol.65,#22,p.15327-15343]

2241677-04-1    154235-83-3 

[1]Hu,Bin;Toda,Kosuke;Wang,Xiaoyu;Antczak,MonikaI.;Smith,Julianne;Geboers,Sophie;Nishikawa,Gen;Li,Hongyun;Dawson,Dawn;Fink,Stephen;Desai,AmarB.;Williams,NoelleS.;Markowitz,SanfordD.;Ready,JosephM.[JournalofMedicinalChemistry,2022,vol.65,#22,p.15327-15343]

Title: Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.

Journal: Schizophrenia bulletin 20120901

Title: Glutamatergic targets for enhancing extinction learning in drug addiction.

Journal: Current neuropharmacology 20101201

Title: Positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor.

Journal: Journal of medicinal chemistry 20101028

Title: Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats.

Journal: Behavioural brain research 20100211

Title: Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting.

Journal: Psychopharmacology 20091101

Title: Systematic review of pharmacological treatments in fragile X syndrome.

Journal: BMC neurology 20090101

Title: Ampakine CX516 ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation.

Journal: Experimental neurology 20081101

Title: Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats.

Journal: Behavioral neuroscience 20080601

Title: A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080201

Title: Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.

Journal: Journal of child and adolescent psychopharmacology 20061001

Title: Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats.

Journal: Pharmacology, biochemistry, and behavior 20060601

Title: Glutamate-based therapeutic approaches: ampakines.

Journal: Current opinion in pharmacology 20060201

Title: Positive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators have different impact on synaptic transmission in the thalamus and hippocampus.

Journal: The Journal of pharmacology and experimental therapeutics 20050401

Title: Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data.

Journal: Psychopharmacology 20050401

Title: Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis.

Journal: Schizophrenia research 20050101

Title: Amphetamine-evoked gene expression in striatopallidal neurons: regulation by corticostriatal afferents and the ERK/MAPK signaling cascade.

Journal: Journal of neurochemistry 20041001

Title: Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus.

Journal: Neuroscience 20040101

Title: Cortex Pharmaceuticals, Inc. Maintaining brain function goes a long way.

Journal: Chemistry & biology 20031101

Title: LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.

Journal: The Journal of pharmacology and experimental therapeutics 20030801

Title: Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action.

Journal: The Journal of pharmacology and experimental therapeutics 20021201

Title: Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors elicits neuroprotection after trimethyltin exposure in hippocampus.

Journal: Toxicology and applied pharmacology 20021201

Title: Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series.

Journal: Schizophrenia research 20021001

Title: Positive modulators of AMPA receptors as a potential treatment for schizophrenia.

Journal: Current opinion in investigational drugs (London, England : 2000) 20020701

Title: CX-516 Cortex pharmaceuticals.

Journal: Current opinion in investigational drugs (London, England : 2000) 20020701

Title: Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model.

Journal: European journal of pharmacology 20020405

Title: Survival signaling and selective neuroprotection through glutamatergic transmission.

Journal: Experimental neurology 20020301

Title: Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report.

Journal: Journal of molecular neuroscience : MN 20020101

Title: Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546.

Journal: Neuropharmacology 20011101

Title: A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.

Journal: Journal of clinical psychopharmacology 20011001

Title: Therapeutic approaches to age-associated neurocognitive disorders.

Journal: Dialogues in clinical neuroscience 20010901

Title: Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator.

Journal: The Journal of pharmacology and experimental therapeutics 20010701

Title: Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.

Journal: Neuropharmacology 20010601

Title: Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo.

Journal: Neuropharmacology 20010601

Title: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.

Journal: Neurology 20000425

Title: Synergistic interactions between ampakines and antipsychotic drugs.

Journal: The Journal of pharmacology and experimental therapeutics 19990401

Title: Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion.

Journal: European journal of pharmacology 19970806

Title: Broberg BV, Glenth?j BY, Dias R, et al. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl). 2009 Nov;206(4):631-40.